《新股消息》奧園(03883.HK)旗下中國文旅集團申請主板上市
中國奧園(03883.HK)為第二大股東的中國文旅集團日前向聯交所申請主板上市,獨家保薦人為國泰君安。
初步招股文件指,中國文旅主要業務為度假物業發展及文化旅遊業務,截至2月29日於恩平及其他地區擁有18個度假物業發展項目組合,其中8個項目已竣工、4個項目發展中,土地儲備總建築面積約160萬平方米。截至去年12月底止,公司收入達5.94億元人民幣(下同),按年增長1.22倍,當中逾80%來自度假物業銷售;年內溢利亦增長近43.5%至1.04億元。
資料顯示,奧園在2017年底斥資約1.4億元入股,於公司上市前持有約28%股份,奧園旗下的文旅項目英德巧克力王國亦由中國文旅負責管理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.